A New Therapeutic Candidate for Cardiovascular Diseases: Berberine

Cardiovascular diseases (CVD) are the leading cause of death in the world. However, due to the limited effectiveness and potential adverse effects of current treatments, the long-term prognosis of CVD patients is still discouraging. In recent years, several studies have found that berberine (BBR) ha...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in pharmacology Vol. 12; p. 631100
Main Authors Cai, Yun, Xin, Qiqi, Lu, Jinjin, Miao, Yu, Lin, Qian, Cong, Weihong, Chen, Keji
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 17.03.2021
Subjects
berberine
cardiovascular diseases
natural product
Pharmacology
safety
therapeutic effects
cardiovascular diseases
therapeutic effects
natural product
safety
berberine
Online AccessGet full text

Cover

More Information
Summary:Cardiovascular diseases (CVD) are the leading cause of death in the world. However, due to the limited effectiveness and potential adverse effects of current treatments, the long-term prognosis of CVD patients is still discouraging. In recent years, several studies have found that berberine (BBR) has broad application prospects in the prevention and treatment of CVD. Due to its effectiveness and safety for gastroenteritis and diarrhea caused by bacterial infections, BBR has been widely used in China and other Asian countries since the middle of the last century. The development of pharmacology also provides evidence for the multi-targets of BBR in treating CVD. Researches on CVD, such as arrhythmia, atherosclerosis, dyslipidemia, hypertension, ischemic heart disease, myocarditis and cardiomyopathy, heart failure, etc., revealed the cardiovascular protective mechanisms of BBR. This review systematically summarizes the pharmacological research progress of BBR in the treatment of CVD in recent years, confirming that BBR is a promising therapeutic option for CVD.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-3
content type line 23
ObjectType-Review-1
This article was submitted to Cardiovascular and Smooth Muscle Pharmacology, a section of the journal Frontiers in Pharmacology
Reviewed by: Hermann Toplak, Medical University of Graz, Graz, ST, Austria
Suowen Xu, University of Science and Technology of China, China
These authors have contributed equally to this work
Edited by: Konrad Urbanek, Magna Græcia University of Catanzaro, Italy
ISSN:1663-9812
1663-9812
DOI:10.3389/fphar.2021.631100